Topical cyclosporine-containing preparations and their use
Stable cyclosporine formulations with nanomicelles address side effects and handling issues, ensuring safety and efficacy in ophthalmic use.
JP7864788B2Active Publication Date: 2026-05-25SUN PHARMACEUTICAL INDUSTRIES LTD
View PDF 6 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- SUN PHARMACEUTICAL INDUSTRIES LTD
- Filing Date
- 2024-08-28
- Publication Date
- 2026-05-25
AI Technical Summary
Technical Problem
Existing ophthalmic formulations containing cyclosporine suffer from side effects such as reduced vision, increased tearing, eye grease, and dysgeusia, and are not stable during handling and at elevated temperatures.
Method used
Formulations containing 0.087 to 0.093% cyclosporine, with nanomicelles of specific particle sizes, are developed, which are stable at elevated temperatures and free of organic solvents, preserving a clear aqueous solution without preservatives.
Benefits of technology
The formulations provide a better safety profile with reduced side effects and improved handling properties, maintaining stability during industrial-scale manufacturing.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007864788000001
Abstract
To provide a topical ophthalmic preparation containing cyclosporin, and a method for producing the preparation.SOLUTION: A topical ophthalmic preparation contains 0.087 to 0.093 wt.% of cyclosporin. In some aspects and embodiments, the preparation may contain polyoxyl lipid or fatty acid and / or polyalkoxylated alcohol, and may contain nanomicelle.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art